Skip to main content
. Author manuscript; available in PMC: 2017 Dec 7.
Published in final edited form as: Nature. 2017 Jun 7;546(7659):498–503. doi: 10.1038/nature22341

Figure 4. iExosomes suppress pancreas cancer progression in KTC GEMM.

Figure 4

(A) Kaplan-Meier curve of KTC (early treatment) mice, Log-rank Mantel-Cox test, siKrasG12D iExo: n=8 mice, Control exos: n=6 mice. (B) Kaplan-Meier curve of KTC mice, Log-rank Mantel-Cox test, siKrasG12D iExo: n=7 mice, shKrasG12D iExo: n=5 mice, Control exos: n=7 mice. (C) Tumor burden (early treatment) at end point. siKrasG12D iExo: n=8 mice, Control exos: n=6 mice. (D) Tumor burden at 44 days of age, n=3 mice per group. (E) H&E stained tumors (scale bar: 100μm, inset scale bar: 50 μm) from 44 days-old KTC mice and relative percentages in histological phenotypes, n=3 mice per group. (F) Masson Trichrome staining (MTS, scale bar: 100μm), TUNEL, Ki-67, and phosphorylated-ERK/CK-19 immunolabeling of 44 days-old KTC mice, n=3 mice per group. (G) KrasG12D transcript levels in tumors of age-matched (44 days old) KTC mice, n=3 mice per group. (H) Tumor volume at baseline (MRI), siKrasG12D iExo: n=6 mice, siScrbl iExo: n=6 mice. (I) Kaplan-Meier curve of KPC mice, Log-rank Mantel-Cox test, n=6 mice in each group. The mean ± SEM is depicted. Unless stated otherwise, unpaired two-tailed t test was used to determine statistical significance. * p<0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. See accompanying source data.